| 1 |
35324532 | Poor response to selpercatinib plus crizotinib in a rearranged during transfection fusion-positive patient with acquired selpercatinib-resistant MNNG HOS transforming amplification: a case report. | 2022 Mar 23 |
1 |
| 2 |
32778510 | A Case of Resistance to Selective RET-TKI Therapy With Pleural-Genotyped MET Amplification and Response to Crizotinib. | 2021 Jan |
1 |
| 3 |
33082208 | Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib. | 2021 Jan 1 |
3 |
| 4 |
34957368 | Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring MET Exon 14 Skipping. | 2021 |
1 |
| 5 |
33324391 | ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1-SHP2 Signaling Pathway in Non-Small Cell Lung Cancer. | 2020 |
1 |
| 6 |
31639374 | ROS-dependent DNA damage contributes to crizotinib-induced hepatotoxicity via the apoptotic pathway. | 2019 Nov 15 |
2 |
| 7 |
31768065 | Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. | 2019 Dec |
1 |